Abstracts tagged "Vasculitis"

Abstract Number: 2416 • ACR Convergence 2023
Comparison of Clinical, Laboratory and Imaging Features of Relapses Between Takayasu and LV-GCA Patients. an Italian Monocentric Study
LUIGI BOIARDI¹, PIERLUIGI MACCHIONI², Francesco Muratore³, Elena Galli⁴, chiara marvisi⁴, Giulia Besutti¹, Lucia Spaggiari¹, Annibale Versari¹ and Carlo Salvarani⁵, ¹IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁵Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: No previous study has compared clinical, laboratory and imaging features of relapses in Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA). The aim…
Abstract Number: 2568 • ACR Convergence 2023
First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients
Michael Chen-Xu¹, Daniel Cooper², Rainer Döffinger², Dr Rachel Jones³ and Rona Smith², ¹Unviersity of Cambridge, Cambridge, United Kingdom, ²University of Cambridge, Cambridge, United Kingdom, ³Addenbrooke's Hospital, Cambridge, United Kingdom
Background/Purpose: Primary systemic vasculitis (PSV) patients on immunosuppression are at higher risk of adverse outcomes following COVID-19 infection and often mount suboptimal vaccine responses to…
Abstract Number: 0203 • ACR Convergence 2023
Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
Zachary Wallace¹, Aaron Wu², Shruthi Srivatsan², Naomi Patel², Jeffrey Sparks³, Eli Miloslavsky², Hyon K. Choi⁴, Peter Merkel⁵, John Stone⁶ and Emily Hyle², ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…
Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Rebecca Kuan¹, Christopher Redmond¹, McKella Sylvester², Mary Maclean¹, Francoise Meylan¹, Marcela Ferrada¹, Kaitlin Quinn¹ and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Colgate University, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
Abstract Number: 0801 • ACR Convergence 2023
LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease
Zhimian Wang, Xin Yu, Hua Chen and Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Dysregulated Th17 cells are implicated in Behçet's disease (BD). However, the underlying mechanism remains unclear. Here we aim to elucidate the mechanism of forkhead…
Abstract Number: 1542 • ACR Convergence 2023
The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study
Zachary Wallace¹, Xiaoqing Fu², Shruthi Srivatsan², Zachary Williams², Claire Cook², Jennifer Hanberg², John Stone³, Hyon K. Choi⁴ and Yuqing Zhang⁵, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…
Abstract Number: 1626 • ACR Convergence 2023
Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study
Shamma Alzaabi¹, Else Bosman¹, David Cabral², Kimberly Morishita¹ and PedVas Investigators Network³, ¹Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada, ²BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ³Pediatric Rheumatology, British Columbia Children Hospital, Vancouver, Canada, Vancouver, BC, Canada
Background/Purpose: Childhood polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation that typically affects small and medium-sized arteries. The clinical presentation is variable; it…
Abstract Number: 2390 • ACR Convergence 2023
Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6
Dimitrios Veroutis¹, Ourania D Argryropouou¹, Andreas Goules², Konstantinos Kambas³, Dimitris Anastasios Palamidas¹, Konstantinos Evangelou¹, Sophia Havaki¹, Aikaterini Polyzou¹, Evangelia Xingi³, Elli Karatza⁴, Kyriaki Boki⁵, alberto cavazza⁶, Christos Kittas¹, Dimitris Thanos⁷, caterina Ricordi⁶, chiara marvisi⁶, Francesco Muratore⁸, Elena Galli⁶, Stefania Croci⁶, Carlo Salvarani⁹, Vassilis G Gorgoulis¹ and Athanasios Tzioufas², ¹National and Kapodistrian University of Athens, Athens, Greece, ²Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Hellenic Pasteur Institute, Athens, Greece, ⁴Laikon General Hospital, Athens, Greece, ⁵Sismanoglion Hospital, Athens, Greece, ⁶Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁷Biomedical Research Foundation of the Academy of Athens, Athens, Greece, ⁸IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Age is the strongest risk factor of giant cell arteritis (GCA), implying a possible pathogenetic role of cellular senescence. So far, no studies have…
Abstract Number: 2417 • ACR Convergence 2023
Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study
LUIGI BOIARDI¹, PIERLUIGI MACCHIONI², Francesco Muratore³, Elena Galli⁴, chiara marvisi⁴, caterina Ricordi⁴, federica Macaluso¹, alberto cavazza⁴, Stefania Croci⁴ and Carlo Salvarani⁵, ¹IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁵Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our…
Abstract Number: 2599 • ACR Convergence 2023
Study of the Role of interleukin-17 in Giant Cell Arteritis
helene Greigert¹, andre ramon², corentin Richard³, claudie cladière⁴, Marion CIUDAD⁵, catherine creuzot-garcher⁶, laurent martin⁷, Sylvain AUDIA¹, romain boidot³, Bernard Bonnotte¹ and Maxime Samson¹, ¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Rheumatology, Dijon University Hospital, Dijon, France, ³Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Dijon, France, ⁶Department of Ophthalmology, Dijon University Hospital, Dijon, France, ⁷Department of Pathology, Dijon University Hospital, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis in which Th17 cells have been identified in excess in lesions and in the blood of patients.…
Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Erika Biegelmeyer¹, Mariana Freitas de Aguiar¹, Priscila Dias Cardoso Ribeiro¹, Ketty Lysie Libardi Lira Machado², Maria da Penha Gomes Gouveia², Camila Maria Paiva França Telles³, Samuel Elias Basualto Dias³, Natália Sarzi Sartori⁴, Thaís Evelyn Karnopp⁵, Vanessa de Oliveira Magalhães¹, Flávia Maria Matos Melo Campos Peixoto¹, Laiza Hombre Dias², Débora Marques Veghini², Rodrigo Vieira de Rezende⁶, Katia Lino Baptista⁶, Ana Karla Guedes de Melo⁷, Vitor Alves Cruz⁸, Maria Cecília Dias Corrêa⁹, Adriana Maria Kakehasi¹⁰, Rejane Maria Rodrigues de Abreu Vieira¹¹, Valderilio Feijó Azevedo¹², Olindo Assis Martins-Filho¹³, Charlles Heldan de Moura Castro¹, Ricardo Xavier¹⁴, Andréa Teixeira-Carvalho¹³, Viviane Angelina de Souza⁹, Odirlei André Monticelo¹⁵, Marcelo Pinheiro¹⁶, Edgard Torres dos Reis Neto¹, Emilia Sato¹, Gilda Ferreira¹⁷, Gecilmara Pileggi¹⁸, Valeria Valim¹⁹ and Alexandre wagner Silva de Souza²⁰, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, ³Universidade Federal do Amazonas, Manaus, Brazil, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal Fluminense, Niterói, Brazil, ⁷Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, ⁸Universidade Federal de Goiás, Goiânia, Brazil, ⁹Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, ¹⁰Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹¹Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, ¹²Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, ¹³Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, ¹⁴Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁵Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁶UNIFESP/ EPM, São Paulo, Brazil, ¹⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁸UNIFESP, Ribeirão Preto, Brazil, ¹⁹Universidade Federal do Espírito Santo, Vitória, Brazil, ²⁰Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…
Abstract Number: 0700 • ACR Convergence 2023
A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta
Elaine Yacyshyn, Simran Gulati, Whitney Hung, Don Voaklander and Allyson Jones, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Systemic vasculitis encompasses a group of autoimmune diseases involving inflammation of blood vessels. Although a rare disease, vasculitis can present with life-threatening symptoms which…
Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Caleb Bolden¹, Claire Cook¹, Lucy Finkelstein-Fox¹, Xiaoqing Fu¹, Flavia Castelino¹, Hyon K. Choi², Cory Perugino¹, John Stone³, Elyse Park¹, Zachary Wallace⁴ and Daniel Hall¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…
Abstract Number: 1543 • ACR Convergence 2023
The Association of Frailty with Outcomes in Patients with Vasculitis
Sebastian Sattui¹, John Stadler², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Peter Merkel⁴ and Robert Spiera⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Hosptial for Special Surgery, New York, NY
Background/Purpose: Frailty is associated with poor health outcomes including increased risk of hospitalizations, infections, and fractures. In the baseline survey of the VascStrong study, we…
Abstract Number: 1646 • ACR Convergence 2023
The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis
Keren Port¹, Ivan Ho Shon¹, Sally Ayesa¹, Rachel Langford¹, Olivia Bennett¹, Andrew Csillag¹, Stacey Fredericks¹, Luz Palacios-Derflingher², Eva Wegner¹ and Anthony Sammel¹, ¹The Prince of Wales Hospital, Sydney, Australia, ²University of New South Wales, Sydney, Australia
Background/Purpose: GCA is a systemic medium-large vessel vasculitis (M-LVV) involving the cranial arteries, aorta and its major branches. Recent studies have shown that PET/CT including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].